We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

18 hedge funds and large institutions have $51.2M invested in Tonix Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

20% more funds holding

Funds holding: 15 → 18 (+3)

0% more ownership

Funds ownership: 0% → 0% (+0%)

40% less capital invested

Capital invested by funds: $85.3M → $51.2M (-$34.1M)

Holders
18
Holders Change
+3
Holders Change %
+20%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.38M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.46M
3
BlackRock
BlackRock
New York
+$974K
4
State Street
State Street
Massachusetts
+$974K
5
Citadel Advisors
Citadel Advisors
Florida
+$487K

Top Sellers

Rank Fund Capital Flow
1
Norges Bank
Norges Bank
Norway
-$3.06M
2
Renaissance Technologies
Renaissance Technologies
New York
-$974K
3
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS)
California
-$487K
4
Millennium Management
Millennium Management
New York
-$487K
5
ECM
ExodusPoint Capital Management
New York
-$239K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$16.4M +$974K +2 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$9.62M – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$4.46M +$1.46M +3 +33%
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
$4.02M +$4.38M +9 +900%
State Street
5
State Street
Massachusetts
$3.99M +$974K +2 +25%
Renaissance Technologies
6
Renaissance Technologies
New York
$3.63M -$974K -2 -18%
Northern Trust
7
Northern Trust
Illinois
$1.96M – – –
N
8
Nuveen
North Carolina
$1.07M – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$603K – – –
Charles Schwab
10
Charles Schwab
California
$531K – – –
VF
11
Virtu Financial
New York
$441K +$487K +1 New
Citadel Advisors
12
Citadel Advisors
Florida
$374K +$487K +1 New
Goldman Sachs
13
Goldman Sachs
New York
$371K +$487K +1 New
Qube Research & Technologies (QRT)
14
Qube Research & Technologies (QRT)
United Kingdom
$325K +$487K +1 New
GCP
15
GSA Capital Partners
United Kingdom
$310K – – –
Deutsche Bank
16
Deutsche Bank
Germany
$225K +$487K +1 New
Prudential Financial
17
Prudential Financial
New Jersey
$206K +$487K +1 New
RhumbLine Advisers
18
RhumbLine Advisers
Massachusetts
$202K – – –
JP Morgan Chase
19
JP Morgan Chase
New York
$173K – – –
Morgan Stanley
20
Morgan Stanley
New York
$157K – – –
Manulife (Manufacturers Life Insurance)
21
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$142K – – –
SG Americas Securities
22
SG Americas Securities
New York
$138K – – –
Millennium Management
23
Millennium Management
New York
$137K -$487K -1 Closed
AllianceBernstein
24
AllianceBernstein
Tennessee
$122K – – –
AIG
25
American International Group
New York
$119K – – –
1
2 3 4

TNXP Hedge Fund Activity: Q3 2021 in Review

18 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2021, worth a combined $51.2M — down 40% from $85.3M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TNXP positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $4.38M. The largest seller was Norges Bank, exiting entirely with an estimated $3.06M sold.

  • 18 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2021, up from 15 in Q2 2021.
  • Funds reported $51.2M of Tonix Pharmaceuticals stock for Q3 2021, down 40% quarter-over-quarter.
  • 6 funds opened new Tonix Pharmaceuticals positions in Q3 2021 and 3 closed out, a net change of +3 holders.
  • The largest Tonix Pharmaceuticals buyer in Q3 2021 was D.E. Shaw & Co, an estimated $4.38M added.
  • The largest Tonix Pharmaceuticals seller in Q3 2021 was Norges Bank, an estimated $3.06M sold.

Based on aggregated 13F filings for Q3 2021.